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e molecular diagnosis of retinal dystrophies is diﬃcult because of the very important number of genes implicated and is rarely
helped by genotype-phenotype correlations. is prompted us to develop IROme, a custom designed in solution-based targeted
exon capture assay (SeqCap EZ Choice library, Roche NimbleGen) for 60 retinitis pigmentosa-linked genes and three candidate
genes (942 exons). Pyrosequencing was performed on a Roche 454GS Junior benchtop high-throughput sequencing platform. In
total, 23 patients aﬀected by retinitis pigmentosa were analyzed. Per patient, 39.6Mb were generated, and 1111 sequence variants
were detected on average, at a median coverage of 17-fold. A�er data �ltering and sequence variant prioritization, disease-causing
mutations were identi�ed in ABCA4, CNGB1, GUCY2D, PROM1, PRPF8, PRPF31, PRPH2, RHO, RP2, and TULP1 for twelve
patients (55%), ten mutations having never been reported previously. Potential mutations were identi�ed in 5 additional patients,
and in only 6 patients nomolecular diagnosis could be established (26%). In conclusion, targeted exon capture and next-generation
sequencing are a valuable and eﬃcient approach to identify disease-causing sequence variants in retinal dystrophies.
1. Introduction
Retinitis pigmentosa (RP) (MIM number 268000) is a
group of genetically highly heterogeneous-inherited reti-
nal dystrophies [1]. Typically, night blindness starts dur-
ing adolescence, and patients progressively loose the rod
photoreceptor-mediated peripheral vision. At later stages,
the cone photoreceptors also become aﬀected, constricting
vision over time to the most central fovea and eventu-
ally resulting in complete blindness. To date, more than
��y genes have been linked to nonsyndromic RP (Ret-
Net; http://www.sph.uth.tmc.edu/RetNet/). Inheritance can
be autosomal dominant (AD), autosomal recessive (AR) or
X-linked, and, rarely, mitochondrial or digenic [2]. Sporadic
or simplex cases account for about 30% [3].
e molecular diagnosis of RP is diﬃcult because (i)
there is no genotype/phenotype correlation in a vast majority
of patients, (ii) a high intra- and interfamilial variability
of clinical phenotypes is observed in patients carrying
the same causative mutation, (iii) diﬀerent mutations in
a same disease-linked gene cause highly variable clinical
phenotypes if not clinically distinct retinal degenerations,
and (iv) overlapping clinical phenotypes and disease-linked
genes exist with additional retinal degenerations, that is,
early-onset Leber congenital amaurosis (LCA), congenital
stationary night blindness (CSNB), cone-rod dystrophies
(CRD), enhanced S-cone syndrome (ESCS), or syndromic
RP in Bardet-Biedl and Usher syndrome [2]. However,
identi�cation of RP-linked sequence variants is important for
genetic counseling and patient management.
Similar to other Mendelian disorders, mutations in RP
patients were identi�ed until recently by linkage mapping
and subsequent Sanger sequencing of candidate genes [4].
Formolecular diagnosis, the validated RPmutations could be



















F 1: Work�ow of the custom-designed targeted exome liquid
hybridization capture assay IROme. Genomic DNA from patients
was fragmented by nebulization and used for shotgun library
construction (454 RocheGSTitaniumRapid Library). Upon adapter
ligation, target enrichment is achieved by hybridizing the pro-
cessed genomic DNA to biotinylated probes (Roche NimbleGen
SeqCap EZ Choice). Aer biotin-streptavidin-based capture and
washing, DNA was ampli�ed by emulsion PCR and sequenced on
a454 Roche GS Junior Sequencer. Sequencing data was aligned
and mapped with the Roche 454 Reference Mapper program.
Figure adapted from Roche NimbleGen technical information
(http://www.nimblegen.com/products/seqcap/index.html).
detected by arrayed primer extension (APEX) chip technol-
ogy [5]. However, a low success rate in detecting mutations
by APEX was inherent to the genetic heterogeneity of RP
patients, and in a cohort of 272 Spanish families aﬀected by
ARRP, causative mutations were identi�ed in only 11% of
them [6].
e development of next-generation sequencing (NGS)
tools in recent years has allowed the production of an
enormous volume of sequencing data at low costs [7].
Whole genome sequencing and downstream data handling
remains cost and labor intensive, limiting its use in routine
mutation detection [8]. Targeted capture of the about 30Mb
of protein-coding regions in the human genome, the so-
called exome, reduced the sequencing and data handling
eﬀort by a factor of 100 and allowed the identi�cation
of mutations in unrelated patients aﬀected by the same
syndrome [9]. Exome sequencing has since been widely used
as a tool for Mendelian disease gene discovery [10, 11].
Initially array-based, targeted sequence capture has become
easy-to-use, thanks to the development of in-solution capture
methods [12]. Finally, benchtop high-throughput sequencers
made exome sequencing available to small-size diagnostic
laboratories [13].
ese technological advances prompted us to develop a
custom designed in solution-based targeted capture assay,
called IROme, for the detection of mutations located in the
exons, including complete 3′-untranslated regions (UTR),
intron-exon boundaries and potential promoter, and 5′-UTR
regions of 63 genes on a 454 GS Junior sequencing platform.
2. Material andMethods
2.1. Patients and DNA Samples. ese studies were approved
by the Swiss Federal Department of Health (authorization
number 035.0003-48) and followed the principles of the
Declaration ofHelsinki.e 23 patients analyzed in this study
were of Swiss, Algerian, and Tunisian origin. Blood samples
were collected aer informed consent. Genomic DNA was
extracted from peripheral blood using a Nucleon BACC2
genomic DNA extraction kit (GE Healthcare, Glattbrugg,
Switzerland). Four patients had been previously analyzed
at Asper Biotech for known RP-linked mutations by APEX
technology [5].
2.2. Design of Solution-Based Capture Assay for Retinitis
Pigmentosa-Linked Genes. Exons of targeted genes were
identi�ed in the reference human genome version hg19
(http://www.ensembl.org/) (Table 1). For each exon 50 bp
were added in both 5′ and 3′ of the exon, including the com-
plete 3′UTR for each gene. Potential alternative transcripts
were also considered in the design. To include potential
proximal promoters, an additional 1000 bp in 5′ of the �rst
exon of each gene, containing the complete 5′-UTR, were
added. e resulting custom-designed SeqCap EZ Choice
library (NimbleGen, Roche) was called IROme, version 1.
2.3. GS Junior Sequencing. e work�ow for GS Junior
sequencing is summarized in Figure 1. DNA concentrations
were measured on a NanoDrop spectrophotometer (ermo
Fisher Scienti�c, Wilmington, DE). 500 ng of gDNA were
fragmented by nebulization, and size selected by Agen-
court AMPure XP beads (Beckman-Coulter, Beverly, MA)
to obtain fragments between 500 and 1200 bp. Adaptors
provided in the GS Titanium Rapid Library Preparation Kit
(Roche, Basel, Switzerland) were ligated to the fragmented
DNA and then quanti�ed by �uorometry (�uantiFluor,
Promega, Madison, WI). is library was ampli�ed by
ligation-mediated (LM)-PCR using speci�c 454 primers.
en, 1 𝜇𝜇g of the PCR ampli�cation product was dried down
with COT-DNA (Roche) and 454-Hybridization Enhancing
Primer in a Speedvac. e pellet was resuspended in Nim-
bleGen’s hybridization buﬀer and hybridized to the custom-
designed SeqCap EZ Choice library (NimbleGen, Roche),
called IROme v1, for 70 h at 47∘C in a thermocycler. e
captured DNA was bound to Streptavidin M-270 Beads
(Invitrogen Dynal, Oslo, Norway) for 45min at 47∘C and,
using a magnet support, washed with the 4 diﬀerent Nim-
bleGen buﬀers provided according to the manufacturer’s
instructions. e captured DNA-Beads were ampli�ed by
LM-PCR using the same speci�c 454 primers as before.
Captured and noncaptured DNA was subjected to quantita-
tive PCR on a Lightcycler480II (Roche, Basel, Switzerland)
to measure the relative fold enrichment of the targeted
sequences. Postcapture samples with an enrichment higher
than 200-fold were further processed. According to the 454
GS Junior protocol (Roche), an emulsion PCR was done on
2 molecules per beads. Aer PCR, the beads were collected,
washed, and bound to the Enrichment Beads. e enriched
BioMed Research International 3
T 1: List of genes enriched by targeted sequence capture (IROme).
Gene Alias Chr Chr location Exons Pathology
ABCA4 RP19, STGD1, CORD3, and ARMD2 1 94458391-94586688 (rs) 50 ADRP, ARRP, ARCRD, and ARMD
AIPL1 LCA4 17 6327057-6338519 (rs) 6 ARLCA, ADCRD
BEST1 RP50, BMD, and VMD2 11 61717293-61732987 (fs) 11 ADRP, ARRP, and ADMD
C2ORF71 RP54 2 29284556-29297127 (rs) 2 ARRP
CA4 RP17 17 58227302-58236902 (fs) 8 ADRP
CABP4 CSNB2B 11 67219877-67226699 (fs) 7 ARLCA, ARCSNB
CEP290 LCA10, BBS14, and NPHP6 12 88442794-88535993 (rs) 53 ARLCA, ARBBS
CERKL RP26 2 182401403-182545392 (rs) 14 ARRP, ARCRD
CLRN1 RP61, USH3A 3 150643950-150690786 (rs) 3 ARRP
CNGA1 RP49 4 47937994-48018689 (rs) 13 ARRP
CNGA2 X 150906923-150913776 (fs) 6
CNGB1 RP45 16 57917847-58005020 (rs) 33 ARRP
CRB1 LCA8, RP12 1 197170592-197447585 (fs) 12 ARRP, ARLCA
CRX LCA7, CORD2 19 48325097-48364769 (fs) 4 ADRP, ADLCA, ARLCA, and ADCRD
DHDDS RP59 1 26758773-26797785 (fs) 9 ARRP
EYS RP25 6 64429876-66417118 (rs) 43 ARRP
FAM161A RP28 2 62051989-62081278 (rs) 6 ARRP
FSCN2 RP30 17 79495422-79504156 (fs) 5 ADRP, ADMD
GUCA1B RP48, GCAP2 6 42152139-42162694 (rs) 4 ADRP, ADMD
GUCY2D LCA1, CORD6 17 7905988-7923658 (fs) 20 ARLCA, ADCRD
IMPDH1 LCA11, RP10 7 128032331-128050306 (rs) 17 ADRP, ADLCA
IMPG2 RP56, sparcan 3 100945570-101039404 (rs) 20 ARRP
IQCB1 NPHP5 3 121488610-121553926 (rs) 15 ARLCA
KLHL7 RP42 7 23145353-23215040 (fs) 12 ADRP
LCA5 Lebercilin 6 80194708-80247175 (rs) 8 ARLCA
LPCAT1 AYTL2 5 1456595-1524092 (rs) 14 ARLCA
LRAT LCA14 4 155548097-155674270 (fs) 4 ARRP, ARLCA
MERTK RP38 2 112656056-112787138 (fs) 19 ARRP
NR2E3 RP37, PNR 15 72084977-72110559 (fs) 8 ADRP, ARRP, and ARESCS
NRL RP27 14 24549316-24584223 (rs) 3 ADRP, ARRP, and ARESCS
OFD1 RP23 X 13752832-13787480 (fs) 23 XRP
OTX2 14 57267426-57277197 (rs) 5 ADLCA
PDE6A RP43 5 149237519-149324356 (rs) 22 ARRP
PDE6B RP40, CSNBAD2 4 619373-664571 (fs) 23 ARRP, ADCSNB
PDE6G RP57 17 79617489-79623607 (rs) 4 ARRP
PRCD RP36 17 74523871-74541458 (fs) 5 ARRP
PROM1 RP41, STGD4, CORD12, and MCDR2 4 15964699-16086001 (rs) 28 ARRP, ADCRD, and ADMD
PRPF3 RP18 1 150293925-150325671 (fs) 16 ADRP
PRPF6 RP60 20 62612488-62664453 (fs) 21 ADRP
PRPF8 RP13 17 1553923-1588154 (rs) 43 ADRP
PRPF31 RP11 19 54618837-54635140 (fs) 14 ADRP
PRPH2 RDS, RP7 6 42664340-42690312 (rs) 3 ADRP, ADMD, ADCRD, and digenic
RBP3 IRBP 10 48381487-48390991 (rs) 4 ARRP
RDH12 LCA13, RP53 14 68168603-68201169 (fs) 8 ADRP, ARLCA
RGR RP44 10 86004809-86019716 (fs) 7 ADRP, ARRP, and ADCA
RHO RP4, CSNBAD1 3 129247483-129254012 (fs) 5 ADRP, ARRP, and ADCSNB
RLBP1 CRALBP 15 89753098-89764922 (rs) 9 ARRP
ROM1 11 62379194-62382592 (fs) 3 ADRP, digenic
RP1 8 55471729-55682531 (fs) 4 ADRP, ARRP
RP2 X 46696375-46741793 (fs) 5 XRP
RP9 PAP1 7 33134409-33149013 (rs) 7 ADRP
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T 1: Continued.
Gene Alias Chr Chr location Exons Pathology
RPE65 LCA2, RP20 1 68894505-68915642 (rs) 14 ARRP, ARLCA
RPGR RP3, CORDX1 X 38128424-38186817 (rs) 19 XRP, XCRD, XMD
RPGRIP1 LCA6, CORD13 14 21756098-21819460 (fs) 24 ARLCA, ARCRD
SAG RP47, Arrestin 2 234216309-234255701 (fs) 16 ARRP, ARCSNB
SEMA4A RP35, CORD10 1 156117157-156147543 (fs) 16 ADRP, ARRP, and ADCRD
SNRNP200 RP33 2 96940074-96971297 (rs) 45 ADRP
SPATA7 LCA3 14 88851268-88936694 (fs) 12 ARLCA
TOPORS RP31 9 32540542-32552551 (rs) 3 ADRP
TUB 11 8040791-8127659 (fs) 13
TULP1 LCA15, RP14 6 35465651-35480715 (rs) 15 ARRP, ARLCA
USH2A RP39 1 215796236-216596738 (rs) 73 ARRP
ZNF513 RP58 2 27600098-27603657 (rs) 4 ARRP
Genes are listed alphabetically according to their oﬃcial gene symbol, and, in addition, gene aliases commonly used in ophthalmic research provided.
Chromosomal (chr) location is based on the Homo sapiens high-coverage assembly GRCh37, yielding in the UCSC hg19 database (fs: forward strand; rs:
reverse strand). For each gene the number of exons is listed. Targeted sequence capturewas directed against genes causing autosomal dominant (AD), autosomal
recessive (AR) X-linked (X), retinitis pigmentosa (RP), and Leber congenital amaurosis (LCA). Other retinopathies caused by a given gene are also indicated:
cone or cone-rod dystrophy (CRD), macular degeneration (MD), congenital stationary night blindness (CSNB), Bardet-Biedl syndrome (BBS), enhanced
S-cone syndrome (ARESCS), and chorioretinal atrophy (CA). Heterozygote ROM1 and PRPH2 mutations cause digenic disease. ORF15 of RPGR was not
included in the assay.
DNA was then eluted and quanti�ed with the provided bead
counter. Sequencing was performed following the 454 GS
Junior protocol. Brie�y, 500′000 enriched DNA beads were
mixed with Packing Beads. en, the PicoTiterPlate (PTP)
was sequentially loaded with Prelayer Beads, DNA-Packing
Beads, Postlayer Beads, and PPiase Beads. Finally, the PTP
was mounted in the 454 GS Junior Sequencer, and the
program was run in full processing for shotgun sequencing.
2.4. Data Analysis. e work�ow for data analysis and
data validation is summarized in Figure 2. Sequencing
data (.s� �le) were analyzed with Roche 454 Reference
Mapper program. Reference text (ref.txt) for gene anno-
tations and the snp131 version of the single nucleotide
polymorphism database (snp131.txt) were downloaded from
the Golden Path database ( http://www.genome.ucsc.edu/).
e sequence variants provided by the 454HCDi�s.txt �le
were �ltered for known SNPs (http://www.ensembl.org/
Homo_sapiens/Gene/Variation_Gene/), type of amino acid
changes (http://genetics.bwh.harvard.edu/pph2/), and repet-
itive sequences. An additional in-house developed program
was used to check the remaining SNPs against reference
sequences obtained in Ensembl. Sequence variants were fur-
ther prioritized according to inheritance, if family informa-
tion was available, and to the percentage of reads containing
a given sequence variant (threshold at 20%). To analyze the
coverage, scripts were written to extract global coverage data
from the 454AlignmentInfo.tsv �le (unique depth, column 5)
and the quality of coverage at each targeted nucleotide (col-
umn4). Part of the sequencing datawas analyzed by Sequence
Pilot version 3.5 (JSI Medicals, Kippenheim, Germany).
2.5. Data Validation. Sanger sequencing validated all
potential pathogenic sequence variants. Brie�y, 20-bp
primers �anking the given region and yielding amplicons
of 300–600 bp were designed (primer sequences available
on request). e polymerase chain reaction (PCR) was
performed in a total volume of 20 𝜇𝜇L, containing 20 ng
genomic DNA, 1mM of each primer (Eurogentec, Liège,
Belgium), and 10 𝜇𝜇L FastStart PCRMasterMix (Roche, Basel,
Switzerland). Ampli�cation was performed in a GeneAmp
9700 thermal cycler (Applied Biosystems, Carlsbad, CA,
USA) with the following conditions: 1min at 95∘C, 35
cycles of 1min at 94∘C, 1min at 58∘C, 1min at 72∘C, and,
a �nal elongation step at 72∘C for 10min. PCR-ampli�ed
products were puri�ed with an Invitek MSB Spin PCRapace
kit (STRATEC Molecular GmbH, Berlin, Germany). Sanger
sequencing was done in a �nal reaction volume of 10𝜇𝜇L,
using BigDye Terminator v3.1 (Applied Biosystems) with
forward and reverse primers. Fragments were separated on
an ABI PRISM 3100 genetic analyzer (Applied Biosystems).
Sequences were analyzed using Chromas 2.23 soware
(Technelysium, Tewantin, QLD, Australia).
3. Results and Discussion
3.1. IROme: Design and Validation of the Assay. e vast
genetic heterogeneity of RP prompted us to develop a
custom-designed hybridization-based targeted exon capture
assay, called IROme. Enrichment was targeted towards a
total of 63 genes (942 exons), of which 60 genes were linked
to RP, LCA, and related retinal dystrophies (Table 1). e
exon ORF15 of RPGR was not included in the assay because
of the presence of repetitive sequences. Two RP- or LCA-
linked genes, IDH3B and RD3, had been reported only in a
single family so far and were not included in this version of
IROme. Conversely, two candidate genes that were linked to
retinal degeneration in mice, but not humans, were added
to the assay (TUB and LPCAT1). A third candidate gene
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F 2: �ork�ow of data analysis and �ltering. e sﬀ (sequence
�le format) �les generated by 454 Roche GS Junior sequencing were
imported either into Reference Mapper or Sequence Pilot soware.
e coding sequence variants were selected from the 454_HCD-
iﬀs.txt �les that contained all sequence variants. During �ltering,
coding sequence variants reported in dbSNP were removed, and
missense and nonsense mutations kept. e remaining coding
sequence variants were prioritized according to known reported
mutations, the mode of inheritance, the percentage of sequence
reads reporting the variant (threshold of 20%), and the predicted
eﬀect on the protein (PolyPhen score).
located on chromosome X, CNGA2, was included because of
its homology to CNGA1. e total of targeted regions spans
394′758 bp.
Of note, aer the design of IROme was completed, TTC8
(BBS8/RP51), C8ORF37, and MAK were linked to RP, and
KCNJ13 and NMNAT1 to LCA. ese latter genes, as well
as IDH3B and RD3, will be included in a future version of
IROme.
Patients 1–4 had previously been investigated by
APEX technology for known RP-linked mutations [5]. All
nucleotides tested by APEX were correctly detected by
IROme, with a 98.9% accuracy of the sequence reads for
nucleotides at a homozygous state (Table 2). A p.USH2A-
V2562A mutation had been detected by APEX in patient 2
in a heterozygous state, and this was correctly validated by
IROme (46.8% of the sequence reads at 47-fold coverage).
As an additional control, the IROme assay was tested on
genomic DNA of a previously described family of Algerian
origin, aﬀected by LCA or early onset retinal degeneration
[14]. e causative 6-base in-frame duplication c. TULP1-
1593_1598dupTTCGCC was readily detected in exon 15
(Table 3, patient 5).
3.2. IROme: Variant Detection, Coverage, and Data Filtering.
A total of 23 RP patients were analyzed by IROme (Table











1 557 100% 25 98.9
2 558 100% 26 99.4
3 558 100% 22 99.2
4 547 100% 20 98.3
enucleotides (nt) tested byAPEX represent validatedRP-linkedmutations
or variants. e mean coverage (cvg) refers to the average of the coverage of
all exons where the mutations are located. e percentage of sequence reads
generated by IROme and correctly calling the nucleotides at homozygous
state are indicated.
3). Pyrosequencing generated an average of 39.6 ± 14.1Mb
per patient, with an average read length of 408 ± 48 bp.
ese long read lengths are comparable to published anal-
yses, where the Roche 454 GS Junior generated the longest
read lengths, in comparison to the other benchtop high-
throughput sequencing platforms, MiSeq (Illumina) and Ion
Torrent PGM (Life Technologies) [13].
On average per patient, 1′111.7 ± 222.2 sequence vari-
ants were found (range: 736–1′826 ). Among these, 90.1±10.0
were located in coding sequences, and a further 42.1 ± 4.7
were changing the amino acid sequence. By considering all
patients, the median coverage was 17-fold, with a maximal
112-fold coverage in one exon of patient 16 (Figure 3). No
coverage was observed for four exons (0.3%): exons 1 of
RP9, IMPDH1, and LPCAT1 and an alternative exon 2 of
CNGA2. ese exons contained GC-rich and/or repetitive
sequences impeding eﬃcient probe design and targeting [15].
Another 15 exons were not covered in all patients (1.6%).
Because these exons were not restricted to the 5′ regions,
absence of coverage was attributed to technical limitations or,
as observed for patient 9, to a deletion (see below).
For patients 20 and 21, two potential heterozygote
mutations had been detected at 22.6% (53-fold coverage)
and 21.3% (61-fold coverage), respectively. However, these
two sequence variants could not be validated by Sanger
sequencing. For further patient analyses, a more stringent
threshold up to 35% of sequence reads might be used for
prioritization of sequence variants. Alternatively, a dynamic
threshold could be implemented, starting at a high stringency
and going down until one or two mutations are identi�ed.
In conclusion, the design of IROme resulted in an over
98% coverage of the targeted exons. e variant detection
work�ow could be improved by further increasing the quality
of the sequencing data, that is, by using a benchtop sequencer
less prone to homopolymer-associated insertion/deletion
errors (e.g., MiSeq, Illumina) [13] and high-�delity DNA
polymerases [16].
3.3. IROme: Molecular Diagnosis on RP Patients. IROme
analysis yielded in de�nite diagnosis for 55% of the RP
patients, that is, 12 out of 23 patients (Patients 4, 5, 8,
9, 10, 11, 12, 13, 16, 17, 19, and 23). is was in line
with the approximately 60% success rate reported for exome








































































































































F 3: Fold coverage of targeted sequences. For each patient the unique depth data provided by column 5 of the 454_AlignmentInfo.tsv
�le was used to estimate the coverage per targeted bp. e onefold coverage data corresponding to reference genome sequences used for
alignment purposes, but not targeted by IROme, were removed.e coverage data is represented as cumulative percentage; that is, indicating
what percentage of targeted bp has a minimal coverage of 𝑥𝑥-fold (𝑥𝑥 axis represents the fold coverage). e average coverage for all patients is
represented as a black dashed line, and the median coverage for all patients is 17-fold.
capture strategies to identify Mendelian disease genes [4],
but represented a 5-fold increase in mutation detection as
compared to the APEX assay [6]. A solution-based targeted
exon capture assay similar to IROme had also identi�ed
disease-causing mutations in 11 out of 17 families aﬀected
by various retinal degenerations (65%) [17]. In contrast,
in a cohort of 100 RP patients, array-based targeted exon
capture resulted in the identi�cation of pathogenic mutations
in 36 individuals (36%) [15]. Amplicon-based approaches
identi�ed potential mutations in 24% of patients aﬀected by
retinal degenerations (5/21) [18], in 79% of ADRP patients
(15/19) [19], and 24% of LCA patients (4/17) [20].
In addition to the control (patient 5), only the p.PROM1-
R373C mutation identi�ed in patient 10 had been previ-
ously described [21], further underscoring the importance of
screening RP-linked genes for the presence of newmutations.
e work�ow for variant detection was not immediately
successful for two patients. For patient 9, a deletion of
exons 45–47 in ABCA4 was only found by analyzing the
coverage data. For patient 16, the 33 bp insertion in PRPF31
was detected by Sequence Pilot, but not Reference Mapper
soware.
Potential mutations were found in three patients (13%).
Patient 1 inherited from her healthy mother a heterozy-
gous p.C2ORF71-R571delRTVVPP mutation and from her
healthy father a heterozygous p.FSCN2-P231S mutation.
Digenic RP has been linked so far to heterozygous PRPH2
and ROM1 mutations [2], and further analyses will be
necessary to validate this molecular diagnostic. Patient 2 and
20 had, respectively, two and one potential mutation, but no
family members were available to con�rm the result.
Results were questionable for two additional patients.
Patient 6 carried a p.RHO-R252Pmutation that had been pre-
viously reported [22]. However, unaﬀected family members
were not available to con�rm this dominant mutation. Also,
a heterozygous p.CRX-Q105X sequence variant was detected
in patient 14, but his healthy mother was also carrying it.
Finally, no molecular diagnostic could be established
for six patients (26%): in patients 18 and 21 no potential
mutations were found by IROme analysis, in patients 7 and
15 the potential mutation did not segregate with disease in
the family, and in patients 3 and 22 heterozygous mutations
were found in genes only reported for recessive inheritance
(CLRN1, EYS).
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3 42.2 416 17.0 1085 78 39 6 1/1 p.CLRN1-P134L 19 68.4 ?
4 44.6 395 21.6 1173 95 42 5 3/3 p.RHO-Y191C 39 38.5 yes
5 24.4 429 13.8 894 104 45 1 1/1 p.TULP1-F529_A530dup 6 100 yes
6 31.7 422 16.2 1039 85 47 1 1/1 p.RHO-R252P 22 54.5 ?







8 13.9 445 9.1 736 70 33 2 1/1 p.RP2-D161Y 22 45.5 yes
9 29 297 17.3 832 80 39 9 1/1 g.ABCA4-ex45-47del 0 0 yes
10 37.3 443 16.7 1247 93 46 3 3/3 p.PROM1-R373C 32 50 yes
11 50.2 440 21.5 1151 92 46 2 1/1 p.RP2-E20X 28 67.8 yes
12 49.1 394 23.8 1116 94 39 9 4/4 p.CNGB1-R765C 30 100 yes
13 33 436 14.6 1017 85 33 3 2/2 p.GUCY2D-V887G 18 94.4 yes
14 32.6 443 15.3 1205 93 42 3 1/1 p.CRX-Q105X 17 58.8 M het norm
15 32.7 442 14.2 1026 86 40 3 1/1 p.USH2A-P2630R 25 40 no
16 69.4 434 28.4 1246 87 41 1 1/1 p.PRPF31-E183_ins33bp 74 40 yes
17 16.7 452 9.8 861 82 43 2 2/2 p.PRPH2-L39P 18 50 yes
18 39.6 429 17.2 1826 85 35 3 1/1
19 66.5 449 26.4 1298 103 45 5 2/2 p.PRPH2-S217_dup16bp 71 39.4 yes
20 47.1 358 19.8 1171 91 47 3 2/1 p.C2ORF71-L889P 23 39.1 ?
21 47 363 17.3 1197 102 48 3 1/0
22 36.6 354 14.7 1072 86 45 2 2/1 p.EYS-D2930G 38 60.5 ?
23 53.3 393 22.4 1164 92 40 7 5/5 p.PRPF8-E2331X 38 44.7 yes
For each patient, the total number of Mb (106 bp) sequenced on the Roche 454 GS Junior (total seq Mb) and the average read length (read length bp) are
indicated. e median fold coverage (cvg) was extracted from the unique depth information. From all the sequence variants (total seq var), �rst only the
sequence variants located in coding sequences were analyzed (cds seq var), with �ltering (�lt seq var) and prioritizing (prio seq var) according to Figure 2.e
sequence variants eventually tested and validated by Sanger sequencing (test/val seq var) are also indicated. For each potential mutation, the coverage (cvg pot
mut) and the percentage of sequence reads reporting the potential mutation (mut reads %) are indicated. For cosegregation analysis, “?” indicates absence of
available family members and/or simplex cases. For patients 1 and 14, the mother (M) and/or the father (F) are healthy heterozygous carriers (het norm).
Of note, all these patients carry novel sequence variants in
noncoding regions. To prioritize for potential disease-causing
sequence variants in these regions, systematic annotation
should not only cover splicing sites, 5′- and 3′-UTRs, but also
implement detailed information about transcription factor
binding sites and regulatory elements located in the potential
proximal promoter regions. Promoter sequence variants
could then be tested by reporter transactivation assays (e.g.,
luciferase reporter assays), but this time-consuming approach
cannot be implemented in a routinemolecular diagnostic lab.
4. Conclusions
e custom designed in solution-based targeted exon capture
assay IROme eﬃciently detected disease-causing mutations
in 55% of RP patients (12/23). A 99.7% coverage of the
targeted regions was obtained. e �rst translated exon o�en
contains sequences with a high GC content in its 5′-UTR
that hinders an eﬃcient capture [23]. Remarkably, more
than 95% of exons 1 (60/63) were successfully enriched
by IROme.In comparison, a pilot study carried out in our
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laboratory on 25 patients using whole exome sequencing
(SureSelect, Agilent) resulted in no coverage of promoter
regions, highly variable coverage of 3′-UTRs, and several
genes had their �rst translated exon very poorly covered.
For instance, the �rst exons of the following RP-linked genes
could not be correctly analyzed: C2ORF71, CA4, CABP4,
CERKL, CNGA1, FAM161A, FSCN2, GUCY2D, IMPDH1,
LPCAT1,MERTK, RDH12, RP9, and RPGR (D. F. Schorderet,
unpublished results). It is tempting to speculate that the
additional sequences upstream of exon 1 included in IROme
further enhanced the performance of the NimbleGen exome
capture technology, that reportedly has more speci�c tar-
geting and a higher percentage of on-target reads than
competing products [23, 24]. However, because the costs
for whole exome sequencing have dramatically decreased
to about 1000 $ per patient, this method may in the future
replace target enrichment and resequencing, providing that a
new line of “whole exome” kits covering eﬀectively all exons,
including the �rst one, of all genes, will become commercially
available [24].
Meanwhile, custom-designed target enrichment and
subsequent next-generation sequencing are a cost-eﬃcient
approach for the molecular diagnosis of retinal dystrophies,
also with respect to the relative ease of data handling and
analysis [25]. Finally, the median global coverage of 17-
fold observed with the IROme assay also indicated the
possibility to include additional retinal degeneration-linked
genes, newly discovered ones or candidate genes.
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